Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu • (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.

The research is led by an Oregon cancer research institute, in collaboration with two biotech companies and the National Institutes of Health.
The ranking measured 79 anatomy/cell biology departments in U.S. medical schools.
The work centers around ReFRAME, a vast collection of drugs developed for other diseases that are already known to be safe for humans.
The goal is material that approaches a diamond in hardness and can survive extreme pressure, temperature and corrosive environments.
This discovery has implications in cancer, stem cell growth, and blood or neuron progenitor cell speciation.
The testing at UAB will investigate immune responses to the vaccine in mice — an important step before any Phase 1 human safety trial in patients later this year.

Francis Collins, M.D., Ph.D., visited UAB just as COVID-19 appeared near the NIH.

An immune reaction to COVID-19 infection called cytokine storm syndrome can be fatal to COVID-19 patients.

The tuberculosis bacteria induce increased hydrogen sulfide production by human macrophages, which increases pathogenesis.

Manipulating cellular metabolism may provide a promising therapeutic intervention in autoimmune diseases.
Page 3 of 32